TY - JOUR
T1 - Update on oxalate crystal disease
AU - Lorenz, Elizabeth C.
AU - Michet, Clement J.
AU - Milliner, Dawn S.
AU - Lieske, John C.
N1 - Funding Information:
Acknowledgments The authors gratefully acknowledge the support of the Rare Kidney Stone Consortium (U54KD083908), a part of NIH Rare Diseases Clinical Research Network (RDCRN), funded by the NIDDK and the NIH Office of Rare Diseases Research (ORDR); the Mayo Clinic O’Brien Urology Research Center (P50 DK083007) funded by the NIDDK; the Mayo Clinic Hyperoxaluria Center; and the Oxalosis and Hyperoxaluria Foundation.
PY - 2013/7
Y1 - 2013/7
N2 - Oxalate arthropathy is a rare cause of arthritis characterized by deposition of calcium oxalate crystals within synovial fluid. This condition typically occurs in patients with underlying primary or secondary hyperoxaluria. Primary hyperoxaluria constitutes a group of genetic disorders resulting in endogenous overproduction of oxalate, whereas secondary hyperoxaluria results from gastrointestinal disorders associated with fat malabsorption and increased absorption of dietary oxalate. In both conditions, oxalate crystals can deposit in the kidney leading to renal failure. Since oxalate is primarily renally eliminated, it accumulates throughout the body in renal failure, a state termed oxalosis. Affected organs can include bones, joints, heart, eyes, and skin. Since patients can present with renal failure and oxalosis before the underlying diagnosis of hyperoxaluria has been made, it is important to consider hyperoxaluria in patients who present with unexplained soft tissue crystal deposition. The best treatment of oxalosis is prevention. If patients present with advanced disease, treatment of oxalate arthritis consists of symptom management and control of the underlying disease process.
AB - Oxalate arthropathy is a rare cause of arthritis characterized by deposition of calcium oxalate crystals within synovial fluid. This condition typically occurs in patients with underlying primary or secondary hyperoxaluria. Primary hyperoxaluria constitutes a group of genetic disorders resulting in endogenous overproduction of oxalate, whereas secondary hyperoxaluria results from gastrointestinal disorders associated with fat malabsorption and increased absorption of dietary oxalate. In both conditions, oxalate crystals can deposit in the kidney leading to renal failure. Since oxalate is primarily renally eliminated, it accumulates throughout the body in renal failure, a state termed oxalosis. Affected organs can include bones, joints, heart, eyes, and skin. Since patients can present with renal failure and oxalosis before the underlying diagnosis of hyperoxaluria has been made, it is important to consider hyperoxaluria in patients who present with unexplained soft tissue crystal deposition. The best treatment of oxalosis is prevention. If patients present with advanced disease, treatment of oxalate arthritis consists of symptom management and control of the underlying disease process.
KW - Calcium oxalate
KW - Crystalline arthropathy
KW - Diagnosis
KW - Enteric hyperoxaluria
KW - Oxalate crystal disease
KW - Oxalosis
KW - Primary hyperoxaluria
KW - Secondary hyperoxaluria
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84877114629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877114629&partnerID=8YFLogxK
U2 - 10.1007/s11926-013-0340-4
DO - 10.1007/s11926-013-0340-4
M3 - Article
C2 - 23666469
AN - SCOPUS:84877114629
SN - 1523-3774
VL - 15
JO - Current rheumatology reports
JF - Current rheumatology reports
IS - 7
M1 - 340
ER -